MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals Operating Cycle 2011-2026 | EGRX
Annual Operating Cycle Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 214 | 272 | 176 | 129 | 163 | 116 | 99.4 | 496 | 180 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 496 | 99.4 | 205 |
Quarterly Operating Cycle Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 397 | 371 | - | 392 | 311 | 152 | - | 259 | 180 | 187 | - | 177 | 182 | 238 | 90.8 | 156 | 110 | 176 | 108 | 206 | 156 | 202 | 105 | 175 | 150 | 57 | 47.5 | 126 | 116 | 161 | 132 | 784 | 809 | 173 | 258 | 440 | 261 | 126 | 42.6 | 51.7 | 46.1 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 809 | 42.6 | 214 |
Operating Cycle of other stocks in the Drug manufacturers industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
576 | - | - | $ 754 M |  USA |
 |
Canopy Growth Corporation
CGC
|
230 | $ 1.06 | - | $ 114 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
16.5 | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
152 | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
121 | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
560 | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
180 | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
146 | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
Evolus
EOLS
|
134 | $ 4.13 | - | $ 266 M | USA |
 |
Alimera Sciences
ALIM
|
181 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
425 | $ 2.6 | - | $ 1.35 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
416 | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
217 | $ 38.6 | - | $ 1.42 B | USA |
 |
Jupiter Wellness
JUPW
|
194 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
198 | $ 0.55 | - | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
614 | $ 4.58 | -5.37 % | $ 64.4 M | USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | Canada |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 3.48 | - | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
247 | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
159 | $ 2.87 | - | $ 378 M | USA |
 |
Emergent BioSolutions
EBS
|
237 | $ 8.92 | - | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
141 | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
459 | $ 11.9 | 1.06 % | $ 845 M | USA |
 |
Radius Health
RDUS
|
220 | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
65.9 | $ 0.9 | -0.12 % | $ 21 M | USA |
 |
Bausch Health Companies
BHC
|
78.9 | $ 5.73 | - | $ 2.09 B | Canada |
 |
Lannett Company
LCI
|
210 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.37 | -3.52 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
201 | $ 11.39 | - | $ 1.58 B | USA |
 |
TherapeuticsMD
TXMD
|
3.34 K | $ 2.22 | -0.89 % | $ 23.2 M | USA |
 |
Pacira BioSciences
PCRX
|
246 | $ 22.1 | - | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
108 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
508 | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
271 | $ 2.52 | - | $ 340 M | USA |
 |
Viatris
VTRS
|
219 | $ 14.89 | - | $ 17.9 B | USA |
 |
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
112 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
176 | $ 0.77 | -1.93 % | $ 3.32 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.75 | 0.33 % | $ 35.9 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
182 | $ 2.75 | - | $ 3.41 M | USA |
 |
Tilray
TLRY
|
222 | $ 7.36 | - | $ 4.55 B | Canada |